KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Net Cash Flow: 2017-2024

Historic Net Cash Flow for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $47.7 million.

  • Aquestive Therapeutics' Net Cash Flow rose 672.15% to $68.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.2 million, marking a year-over-year decrease of 3.41%. This contributed to the annual value of $47.7 million for FY2024, which is 1501.76% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Net Cash Flow of $47.7 million as of FY2024, which was up 1,501.76% from -$3.4 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Net Cash Flow high stood at $47.7 million for FY2024, and its period low was -$17.5 million during FY2020.
  • For the 3-year period, Aquestive Therapeutics' Net Cash Flow averaged around $14.5 million, with its median value being -$751,000 (2022).
  • As far as peak fluctuations go, Aquestive Therapeutics' Net Cash Flow slumped by 352.86% in 2023, and later skyrocketed by 1,501.76% in 2024.
  • Aquestive Therapeutics' Net Cash Flow (Yearly) stood at -$17.5 million in 2020, then surged by 78.41% to -$3.8 million in 2021, then spiked by 80.15% to -$751,000 in 2022, then tumbled by 352.86% to -$3.4 million in 2023, then skyrocketed by 1,501.76% to $47.7 million in 2024.